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osting by EAbstract Purpose: To report the late complications associated with permanent ﬁller injections
into the malar area for rejuvenation.
Methods: A retrospective case series of three patients who presented with lower eyelid swelling sev-
eral years following injection of polyalkylimide (Bio-Alcamid) into the malar area.
Results: All patients presented with lower eyelid swelling which developed as a result of spontane-
ous migration of ﬁller to the lower eyelid. Iatrogenic migration of the ﬁller from the lower eyelid
following a trial to remove resulted in an abscess formation which further complicated the removal.
Conclusions: Lower eyelid swelling may be one of the late complications associated with the per-
manent ﬁllers into the malar area. An attempt at removal of ﬁller by aspiration or bimanual expres-
sion may result in late migration of the product and the development of eyelid swelling.
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lsevier1. Introduction
Age-related volume loss, increased skin laxity, fat loss, fat
redistribution, and diminished support from underlying muscle
and bone result in observable––and sometimes profound––
changes in the aging face. Soft tissue volume loss, particularly
in the periorbital and malar areas, is one of the hallmarks of
the aging face (Friedman, 2005).
The increasing number of individuals seeking medical solu-
tions for their aging skin or for purely aesthetic and cosmetic
indications has led to the recent popularity of many different
types of dermal and subdermal ﬁllers. Malar area augmenta-
tion is one of the most common usages of these ﬁllers.
The characteristics of an ideal ﬁller include bring inexpen-
sive, safe, painless to inject, hypoallergenic, long lasting, reli-
able (i.e., produces consistent and predictable results),
natural feeling under the skin, and easily injectable. In addi-
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complications without the need for harvesting from other sites
(Brandt and Cazzaniga, 2007). The pharmaceutical industry
has responded by providing the cosmetic surgeon with an
increasing number of options to meet the increasing demands
of consumers.
The purpose of this report is to resent our experience of
dealing with late complications of ﬁllers for the facial
rejuvenation.
2. Methods
A retrospective case series of three patients who developed
lower eyelid swelling several years following soft tissue aug-
mentation of the malar area with injectable ﬁllers. Information
obtained included age, gender, types of ﬁllers used, time and
site of injections, past medical history, any prior procedures
performed before presentation, and complete ophthalmic
examination ﬁndings.
3. Results
3.1. Case 1
A 45-year-old female presented with a 3-month history of
spontaneous, nonpainful left lower eyelid swelling. The patient
had undergone augmentation of the malar area on both sides
with polyalkylimide (Bio-Alcamid) injection 4 years earlier.
There was no history of other surgeries.
Examination revealed diffuse, non-tender, ﬁrm mass of the
right lower eyelid area without any skin changes (Fig. 1A). The
rest of the ophthalmological evaluation was unremarkable for
both eyes. The mass was found to be anterior to the orbitalFigure 1 (A) A 45-year-old female presented with spontaneous, no
polyalkylimide (Bio-Alcamid) into malar area of both sides. (B) Six m
with development of mild lower eyelid retraction.
Figure 2 (A) A 32-year-old female presented with nonpainful right low
needle to remove part of the polyalkylimide (Bio-Alcamid) material tha
months following removal of the mass through a subciliary incision wseptum. The lesion was removed through a subciliary incision.
Histopathological examinations of the removed mass revealed
foreign body giant cell reaction around the ﬁlling material.
Postoperatively, the patient developed mild lower eyelid
retraction (Fig. 1B).
3.2. Case 2
A 32-year-old woman presented with a 4-month history of dif-
fuse swelling over the right lower eyelid, which had slightly
increased in size recently. The patient had polyalkylimide
(Bio-Alcamid) injections over the malar area 5 years prior to
presentation. A few weeks earlier, the patient underwent aspi-
ration of the part of the polyalkylimide (Bio-Alcamid) material
which had migrated from its original place at the malar area.
There was no history of any previous surgeries or other inject-
able ﬁllers.
Examination revealed diffuse, non-tender, ﬁrm mass of the
right lower eyelid, without any skin changes (Fig. 2A). The rest
of the ophthalmological examination was unremarkable. The
mass was found anterior to the orbital septum which was re-
moved through a subciliary incision.
Histopathological examination of the removed mass re-
vealed foreign body giant cell reaction around the ﬁller mate-
rial (Fig. 3). Postoperatively, the patient was doing well at the
6-month follow-up (Fig. 2B).
3.3. Case 3
A 38-year-old woman underwent bilateral augmentation of the
malar area with injection of polyalkylimide (Bio-Alcamid).
Two years later, she noticed some swelling at the right lower
eyelid area. A trial aspiration of the area was performed. Threenpainful left lower eyelid swelling 4 years following injection of
onths following removal of the mass through a subciliary incision
er eyelid swelling a few weeks following a trial of aspiration with a
t had moved from its original place in the right malar area. (B) Six
ith very good eyelid position.
Figure 3 Histopathology the removed mass from the second patient was found to have foreign body giant cell reaction (yellow arrows)
around the ﬁlling material (violet) (hematoxylin and eosin stain, ·10).
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pain and swelling in the lower eyelid and was referred for fur-
ther management.
Severe tenderness and swelling with abscess collection over
the right lower eyelid was found upon examination (Fig. 4A).
Drainage of the abscess was performed through stab incisions,
and the drained pus revealed Staphylococcus aureus from cul-
tures. The patient was treated with oral amoxicillin with clav-
ulanic acid (Fig. 4B) and responded well.
4. Discussion
As the skin ages, the dermis gradually loses its major natural
constituents: collagen, elastin, and hyaluronic acid. Collagen
acts as the major support protein for the skin; elastin allows
skin to stay ﬁrm and elastic and to resist wrinkles; hyaluronic
acid helps to trap water and add volume and shape to the skin,
giving it its plumpness (Elson, 1995; Lupo, 2006). Soft tissue
augmentation with dermal ﬁllers can successfully address someFigure 4 (A) A 38-year-old woman presented with right lower eyelid
remove part of the polyalkylimide (Bio-Alcamid) material that had mov
following drainage of the abscess and treatment with two weeks coursof these signs of aging by ﬁlling soft tissue defects, scar forma-
tion, or disease process. Soft tissue augmentation with dermal
ﬁllers has gained widespread acceptance as an alternative to
more aggressive, invasive treatment of the aging face (Murray
et al., 2005). Dermal ﬁllers, which can be matched appropri-
ately to the cosmetic defects when, injected with proper tech-
niques, and implanted at the optimal depth may provide
excellent cosmesis with little or no downtime (Monheit, 1992).
In recent years, the number of available ﬁlling agents––both
permanent and non-permanent types––has increased dramati-
cally. The readily availability of several agents has improved
the range of options for physicians and patients. Non-perma-
nent (resorbable) ﬁllers, such as collagen and hyaluronic acid
products are the most commonly used soft tissue augmentation
products. These products are generally well tolerated and re-
quire a performance of skin test for tolerance to collagen ob-
tained from bovine tissue. Total resorption of these products
occurs over a period of 3–12 months, depending on the patient.
As a consequence, repeat injections are required at frequentabscess few days following a trial of aspiration with a needle to
ed from its original place in the right malar area. (B) Three months
e of systemic antibiotics.
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correction.
Injectable ﬁllers have been used for lip enhancement and
malar augmentation and for the correction of depressed facial
scars, nasolabial folds, marionette lines, tear troughs, and gla-
bellar frown lines. Treatment is tailored to the patient’s indi-
vidual needs so as to achieve maximal beneﬁt, minimize risk,
and obtain the desired correction longevity.
Injectable soft tissue ﬁllers are generally injected into the
dermal layer because of the presence of ﬁbroblasts in the extra-
cellular matrix and vasculature allows the incorporation of
material by the host (Cohen, 2008; Sherman, 2009). Because
of implant nodularity and palpability, some materials can be
placed in the subcutaneous layer instead (Homicz and Watson,
2004).
Hyaluronic acid ﬁllers (labeled by some as the ‘‘key to the
fountain of youth’’) have gained in popularity as dermal ﬁlling
agents for soft tissue augmentation for three reasons (Brandt
and Cazzaniga, 2007). First, hyaluronic acid ﬁllers have a po-
sitive effect on soft tissue augmentation. Hyaluronic acid, the
most prominent glycosaminoglycan in the skin, potently binds
to water. When it is injected into the skin, hyaluronic acid vol-
umizes, softens, and hydrates the skin by stabilizing intercellu-
lar structures and producing a viscoelastic network for
collagen and elastin ﬁbers to bind together. Second, the risk
of allergy is remote with hyaluronic acid because it is identical
in all species. Third, hyaluronic acid ﬁllers are considered long
lasting because they are effective for approximately 6–
12 months (Beasley et al., 2009).
Even with excellent technique, minor adverse effects can
occasionally occur with the injection of almost any dermal ﬁl-
ler. Some of these adverse effects include burning at the injec-
tion site, itching, pain, erythema, edema, bruising, or
hematoma formation which tend to occur soon after injection
and are usually temporary. They may be managed with ice
packs, warm compresses, or watchful waiting. In rare cases,
erythema may persist and require treatment.
Major adverse effects associated with the dermal ﬁllers can
be avoided with proper technique and care. For example,
bleeding can be decreased by having patient refrain from tak-
ing all blood thinner medications for 10 days before treatment
(Rao et al., 2005).
Other major adverse effects include the appearance of pal-
pable nodules and delayed-onset granulomas which can be de-
creased by linear threading, which reduces the risk of nodules
(Lowe et al., 2005; Lemperle, 2006). Triamcinolone acetonide
may be administered to treat these granulomas (Lemperle,
2006).
The permanent ﬁllers available contain polyacrylamide
(Aquamid), polyalkylimide (Bio-Alcamid), and collagens com-
bined with polymethylmethacrylate or hydroxyethylmethacry-
late. These ﬁllers have to be injected in the subcutaneous or
supraperiosteal plane. Because of the serious complications
associated with the injection of permanent ﬁllers have limited
their use.
Polyalkylimide, a nonresorbable polymeric material, is
composed of apyrogenic water (96%) and an alkylimide–
amide group (4%). When polyalkylimide is injected, it be-
comes enclosed within a thin collagen capsule. The few studies
investigating the physical and biological characteristics of
polyalkylimide have recently reported that it is (1) a completelybiocompatible substance, (2) absolutely nontoxic and nonaller-
genic, and (3) easily injectable (Ellis and Sardesai, 2008; Ra-
mires et al., 2005). When administered properly,
polyalkylimide may be suitable for soft tissue augmentation
and correction of tissue deﬁciencies in posttraumatic injuries,
surgical scars, and congenital facial and body microgenia,
and for cosmetic applications (Ellis and Sardesai, 2008; Ra-
mires et al., 2005). Polyalkylimide should be injected into sub-
dermal fat or connective tissue. However, if it is not injected in
the subdermal preperiosteal plane at the initial treatment,
migration may subsequently occur (Ross and Malhotra,
2009; Karim et al., 2006; Schelke et al., 2009). Aspiration
and bimanual expression are performed to remove the mi-
grated product; however, this process may precipitate long-
term migration of the product (Ross and Malhotra, 2009;
Schelke et al., 2009).
In summary, the diagnosis and treatment of lower eyelid
swelling that occurs late following the injection of poly-
alkylimide represent challenges for many clinicians. Our pa-
tients presented with unusual complications, including
abscess formation, migration, and persistent swelling, sev-
eral years following injection of polyalkylimide into the ma-
lar area. However, migration of the product does not
typically occur because of its hydrophilic and endoprosthet-
ic nature. These complications are more likely to happen
after an attempt has been made to remove the product,
resulting in the disruption of the collagen capsule surround-
ing the ﬁller.
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